We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Clinical Reference · Medically Reviewed
A side-by-side clinical comparison written by board-certified menopause specialists — so you know exactly where you are and what to do next.
Reviewed by Kindr Health Clinical Team · Last reviewed 2026-07-03
In perimenopause, the goal is to smooth out hormonal volatility — symptoms come from fluctuation, not just decline. Cyclic or continuous hormone therapy may be appropriate, often at lower doses than postmenopausal regimens. Mental wellness support and sleep optimization carry outsized impact during this stage.
In menopause and postmenopause, the goal is to restore physiologic estrogen to relieve symptoms and reduce the long-term risks of hypoestrogenism (bone loss, genitourinary syndrome, cardiovascular changes). Standard regimens use transdermal estradiol with micronized progesterone for women who still have a uterus.
Specialized treatment for the transition years.
Menopause HRT →Bioidentical hormone therapy for menopause and beyond.
Take the symptom checker →2 minutes. Personalized starting point.
Perimenopause begins the year cycles start behaving differently — often in the late 30s or early 40s — and ends 12 months after the final menstrual period. Hormonally, it is the most volatile stage of a woman's life: estradiol swings 30% higher than reproductive baseline on some days and drops to postmenopausal levels on others. Progesterone declines first and more steeply, which is why sleep, mood, and cycle changes usually appear years before hot flashes.
Menopause is the retrospectively-assigned date of the final menstrual period (FMP), confirmed only after 12 consecutive months of amenorrhea with no other identifiable cause. The average FMP in the U.S. is age 51.4. Menopause before 40 is primary ovarian insufficiency and requires a different clinical workup, including autoimmune, chromosomal, and iatrogenic screens.
Postmenopause begins the day after that 12-month mark and lasts the rest of a woman's life. Estradiol stays persistently below 20 pg/mL, FSH stays above 30 mIU/mL, and the tissues that carry estrogen receptors — bone, vasculature, brain, skin, urogenital lining — begin to change measurably within 5 years without intervention.
Because estradiol and FSH oscillate dramatically week-to-week, a single serum draw is essentially a snapshot of the wrong moment. NAMS, ACOG, and the Endocrine Society all recommend against routine FSH or estradiol testing for perimenopausal diagnosis in women over 45 with symptoms and cycle changes — the diagnosis is clinical. Labs become useful only in three scenarios: symptoms before age 40 (evaluating for POI), women without a uterus who can't use cycle irregularity as a marker, and unexplained secondary amenorrhea in the reproductive years.
Most textbook "menopause symptoms" — hot flashes, sleep disruption, brain fog, mood volatility, joint pain, palpitations — begin in perimenopause, not after the FMP. In the SWAN cohort (the largest longitudinal study of the menopause transition), 82% of women reported vasomotor symptoms during perimenopause, with a median duration of 7.4 years. Symptoms that are more distinctly postmenopausal include vaginal dryness and painful intercourse (genitourinary syndrome of menopause), accelerating bone loss, and a measurable rise in visceral adiposity and LDL-C.
Randomized trials (KEEPS, ELITE) and reanalyses of the Women's Health Initiative converge on the same conclusion: starting hormone therapy within 10 years of the final menstrual period, or before age 60, produces a materially different risk-benefit profile than starting later. In the early window, HRT reduces all-cause mortality, preserves bone and vascular structure, and does not increase cardiovascular events. Started 20 years after menopause into already-diseased vasculature, the same molecule produces different outcomes. Perimenopause is inside that early window by definition — which is why kindr clinicians treat perimenopausal symptoms actively rather than telling patients to "wait until it's real menopause."
Fertility declines steeply after 37 but is not zero until 12 months of amenorrhea have passed. Unplanned pregnancies in women over 45 are more common than most patients realize. Effective options during perimenopause include the levonorgestrel IUD (which also treats heavy perimenopausal bleeding), progestin-only pills, and combined oral contraceptives when there is no smoking history, migraine with aura, or elevated cardiovascular risk. IUDs and progestin-only methods can also serve as the progesterone component of transdermal-estrogen HRT.
Perimenopause is the years of hormonal fluctuation while you still get periods (even irregular ones). Menopause is the moment you have gone 12 consecutive months without a period. The years afterward are postmenopause.
Yes. Hormone therapy is FDA-approved and evidence-supported for symptomatic perimenopausal women. Kindr providers tailor regimens differently in perimenopause vs. postmenopause because remaining cycle activity changes the dosing strategy.
Approximately 51 years in the United States. Menopause before age 40 is called premature ovarian insufficiency and warrants specialized evaluation.
No. Many women experience hot flashes during late perimenopause — sometimes years before their last period.
No. Treatment is offered when symptoms interfere with sleep, mood, work, relationships, or quality of life. Severity — not stage — drives the decision.
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026